UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4568) 4568
Book Chapter (83) 83
Magazine Article (19) 19
Dissertation (6) 6
Newspaper Article (5) 5
Conference Proceeding (3) 3
Reference (2) 2
Paper (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
trastuzumab (4096) 4096
humans (3730) 3730
science & technology (3499) 3499
life sciences & biomedicine (3342) 3342
female (3013) 3013
oncology (2504) 2504
breast neoplasms - drug therapy (2454) 2454
breast cancer (2215) 2215
middle aged (1472) 1472
antibodies, monoclonal, humanized (1459) 1459
breast neoplasms - pathology (1397) 1397
antineoplastic combined chemotherapy protocols - therapeutic use (1386) 1386
adult (1193) 1193
cancer (1143) 1143
aged (1136) 1136
receptor, erbb-2 - metabolism (1129) 1129
chemotherapy (1009) 1009
tumors (978) 978
treatment outcome (884) 884
antibodies, monoclonal - administration & dosage (868) 868
antineoplastic agents - therapeutic use (862) 862
breast neoplasms - metabolism (760) 760
biological and medical sciences (729) 729
antibodies, monoclonal, humanized - administration & dosage (726) 726
medical sciences (722) 722
antibodies, monoclonal - therapeutic use (666) 666
antineoplastic agents (665) 665
her2 (653) 653
care and treatment (647) 647
animals (645) 645
trastuzumab - administration & dosage (645) 645
metastasis (640) 640
skin and connective tissue diseases (631) 631
medicine & public health (569) 569
antineoplastic agents - administration & dosage (554) 554
erbb-2 protein (554) 554
breast neoplasms - genetics (528) 528
receptor, erbb-2 - genetics (515) 515
epidermal growth factor (503) 503
cell line, tumor (490) 490
cancer therapies (483) 483
research (461) 461
antineoplastic combined chemotherapy protocols - adverse effects (460) 460
receptor, erbb-2 - antagonists & inhibitors (458) 458
disease-free survival (456) 456
drug therapy (453) 453
pharmacology & pharmacy (452) 452
antineoplastic agents - adverse effects (451) 451
chemotherapy, adjuvant (445) 445
prognosis (444) 444
gynecology. andrology. obstetrics (437) 437
mammary gland diseases (424) 424
mice (424) 424
paclitaxel - administration & dosage (412) 412
neoplasm staging (396) 396
taxoids - administration & dosage (396) 396
antibodies, monoclonal, humanized - therapeutic use (392) 392
neoplasm metastasis (388) 388
breast neoplasms - mortality (381) 381
aged, 80 and over (372) 372
analysis (369) 369
male (362) 362
antimitotic agents (361) 361
patients (360) 360
monoclonal antibodies (358) 358
pharmacology. drug treatments (357) 357
neoplasms (355) 355
receptor, erbb-2 - analysis (354) 354
antibodies, monoclonal - adverse effects (337) 337
clinical trials (334) 334
neoadjuvant therapy (333) 333
health aspects (313) 313
hematology, oncology and palliative medicine (305) 305
retrospective studies (299) 299
antineoplastic combined chemotherapy protocols - administration & dosage (281) 281
antineoplastic agents - pharmacology (280) 280
lapatinib (278) 278
antibodies, monoclonal, humanized - adverse effects (277) 277
metastases (274) 274
trastuzumab - therapeutic use (273) 273
immunohistochemistry (265) 265
drug administration schedule (264) 264
metastatic breast cancer (258) 258
quinazolines - administration & dosage (252) 252
pertuzumab (244) 244
trastuzumab - adverse effects (241) 241
cancer research (238) 238
clinical trials as topic (238) 238
anthracyclines (234) 234
stomach neoplasms - drug therapy (233) 233
cardiotoxicity (231) 231
receptor, erbb-2 - biosynthesis (221) 221
receptor, erbb-2 - immunology (221) 221
deoxycytidine - analogs & derivatives (218) 218
survival analysis (218) 218
risk factors (216) 216
antibodies, monoclonal - pharmacology (214) 214
fluorouracil - administration & dosage (211) 211
abridged index medicus (207) 207
breast neoplasms - surgery (206) 206
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4449) 4449
Japanese (162) 162
French (58) 58
German (42) 42
Chinese (30) 30
Russian (20) 20
Spanish (11) 11
Portuguese (10) 10
Hungarian (8) 8
Italian (6) 6
Norwegian (4) 4
Danish (2) 2
Polish (2) 2
Turkish (2) 2
Croatian (1) 1
Dutch (1) 1
Hebrew (1) 1
Korean (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of clinical oncology, ISSN 0732-183X, 07/2014, Volume 32, Issue 19, pp. 2078 - 2099
Journal Article
The New England journal of medicine, ISSN 0028-4793, 02/2020, Volume 382, Issue 7, pp. 597 - 609
Journal Article
Nature (London), ISSN 0028-0836, 03/2020, Volume 579, Issue 7799, pp. 421 - 426
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Coumarins - metabolism | Inflammation - pathology | Humans | Silanes - pharmacokinetics | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Mammary Neoplasms, Experimental - metabolism | Silanes - metabolism | Inflammation - metabolism | Proteins - administration & dosage | Delayed-Action Preparations - pharmacokinetics | Trastuzumab - metabolism | Oligopeptides - chemistry | Trastuzumab - chemistry | Silanes - chemistry | Proteins - pharmacokinetics | Silanes - administration & dosage | Immunoconjugates - metabolism | Trastuzumab - administration & dosage | Oligopeptides - metabolism | Delayed-Action Preparations - metabolism | T-Lymphocytes - immunology | Mice | Mice, Inbred BALB C | Oligopeptides - administration & dosage | HeLa Cells | Mammary Neoplasms, Experimental - immunology | Trastuzumab - pharmacokinetics | Immunoconjugates - pharmacokinetics | Coumarins - chemistry | Delayed-Action Preparations - chemistry | Immunoconjugates - administration & dosage | Delayed-Action Preparations - administration & dosage | Green Fluorescent Proteins - administration & dosage | Mammary Neoplasms, Experimental - pathology | Female | Green Fluorescent Proteins - chemistry | Green Fluorescent Proteins - metabolism | Oligopeptides - pharmacokinetics | Coumarins - administration & dosage | Coumarins - pharmacokinetics | Inflammation - immunology | Immunoconjugates - chemistry | Xenograft Model Antitumor Assays | Animals | Proteins - metabolism | Inflammasomes - immunology | Green Fluorescent Proteins - pharmacokinetics | Proteins - chemistry | Pyroptosis - immunology | Immune response | Antibodies | Fluorescence | Selectivity | Fluorides | Electron microscopy | Mammalian cells | Nanoparticles | Proteins | Transmission electron microscopy | Sodium | Mutation | Trastuzumab | Tumors | Apoptosis | Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 12/2018, Volume 29, Issue 12, pp. 2328 - 2333
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Lapatinib | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Ultrasonic imaging | Surgery | Diarrhea | Cytotoxicity | Ligands | Cancer therapies | Tumors | Medical research | Mammography | Kinases | Index Medicus | Abridged Index Medicus | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article